Japan’s health ministry said on Monday that its panel of experts had agreed to approve manufacturing and sales of AstraZeneca’s COVID-19 preventive treatment Evusheld.
The White House said it will hold a summit aimed to address issues around U.S. hunger, nutrition and health on Sept. 28 in Washington, D.C.
Novartis said on Monday its Scemblix was approved by the European Commission for adult patients with chronic myeloid leukemia (CML), offering a new treatment approach for patients with intolerance to other therapies.
Germany’s Bayer said on Sunday it was starting a Phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.
AstraZeneca’s blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalization and death in people with all types of heart failure, according to study data released on Saturday, opening the door to a substantial increase in patients who could benefit.
Abbott Laboratories has restarted production of its Similac infant formula at the plant in Sturgis, Michigan at the center of the U.S. baby formula shortage.
Most doses of Bavarian Nordic’s two-dose Jynneos monkeypox vaccine administered in the United States have been first doses, U.S. Centers for Disease Control and Prevention Director Rochelle Walensky said on Friday.
Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.
The report summarizes various measures of the pharmaceutical industry’s ability to deliver quality drugs to U.S. patients and consumers.
In a Securities and Exchange Commission report filed Thursday, Zymergen revealed it is cutting 80 more jobs and parting ways with Zach Serber, its co-founder and chief scientific officer, on Sept. 22.
